Exactech: The Orthopedic Implant Company Whose FDA Recall of Faulty Packaging Left Thousands of Patients Facing Premature Joint Failure

Exactech Inc., a Gainesville, Florida-based orthopedic implant manufacturer, issued an FDA-supervised recall of approximately 147,000 knee, hip, and ankle replacement components after the company disclosed that nonconforming packaging had been used for the products over a period spanning more than a decade — packaging that did not include a required oxygen barrier layer, allowing oxygen infiltration that oxidized the polyethylene bearing surfaces of the implants and dramatically increased the risk of premature component failure requiring revision surgery.DOCUMENTED

The Exactech recall was among the most significant orthopedic device safety events in recent years, not only for its scale — affecting patients across the United States and internationally — but for its duration, since the packaging defect had been present in products manufactured over an extended period and had affected a substantial portion of the company's joint replacement implant line. Patients who had received the recalled components faced an elevated risk of joint failure years before the expected lifespan of the implant, with potential need for revision surgery that carries its own substantial medical and personal consequences.

Why Polyethylene Packaging Matters in Orthopedics

The polyethylene bearing surfaces used in joint replacement implants — the plastic components that interface with the metal components of the prosthesis to provide articulating surfaces — are sensitive to oxidation, which degrades their material properties and reduces their wear resistance. Manufacturers of orthopedic implants package polyethylene components in vacuum-sealed pouches with multiple barrier layers designed to exclude oxygen during the product's shelf life, because even modest oxygen exposure during storage can initiate oxidative degradation that continues in vivo after implantation. The industry standard requires packaging that maintains a low-oxygen environment from the point of manufacturing through the point of surgical implantation, which may be years after the product was packaged.REVIEWED

Exactech's recall disclosed that a manufacturing process deviation had resulted in the use of packaging that lacked the required oxygen barrier layer across a substantial portion of the company's polyethylene component production over an extended period. The company's quality system had not detected the nonconformance during the affected production period, and the defect was identified only when the company conducted a systematic review of its packaging materials and specifications. By that point, tens of thousands of the nonconforming components had been implanted in patients who were now at elevated risk of premature implant failure.DOCUMENTED

The Clinical Consequences of Oxidized Polyethylene

Polyethylene oxidation in orthopedic implants has been studied extensively because it was a significant cause of implant failure in early generations of total joint replacement. Oxidized polyethylene wears faster than properly protected material, generating wear debris that can cause an inflammatory reaction in the surrounding tissue — a process called osteolysis — that may cause bone loss around the implant and ultimately compromise its fixation. In severe cases, oxidized polyethylene inserts can fracture, causing sudden and complete implant failure. The time course over which oxidation causes clinical symptoms varies based on the degree of oxidation, the patient's activity level, and the specific implant design, meaning that some patients with the recalled Exactech components were already experiencing symptoms while others had not yet reached the point of clinically significant wear.REVIEWED

For patients who had received the recalled components, the recall created a difficult medical situation: their implant was not yet necessarily failing, but it carried an elevated risk of failure that their surgeon could not precisely quantify for the individual patient. The appropriate clinical response — whether to monitor and wait, to plan prophylactic revision, or to revise based on imaging evidence of early wear — required individualized assessment by the treating orthopedic surgeon, guided by the recall information and whatever additional guidance Exactech and orthopedic professional societies provided. Patients who had received the recalled components and had not yet been contacted by their orthopedic surgeon were advised to proactively seek an evaluation to assess the status of their implant.

A packaging defect that exposes an orthopedic implant to oxygen is not a cosmetic problem. It starts a clock on the implant's failure — and the patient only finds out when the pain returns or the joint gives way.

Regulatory and Legal Consequences

The FDA's oversight of Exactech's recall required the company to notify all known implanting surgeons and hospitals, establish a process for identifying patients who had received the recalled components, and provide guidance to treating physicians on monitoring and management. Exactech's obligation extended to making information available to help patients understand their risk and to work with the healthcare system to ensure that patients who needed evaluation received it — a significant operational undertaking given the scale of the recall and the number of healthcare facilities that had used the products over the affected period.DOCUMENTED

The recall generated substantial product liability litigation from patients who had experienced premature implant failure and required revision surgery. Revision surgery for total knee or hip replacement is a substantially more complex procedure than the original implantation, carries higher surgical risks, typically involves longer recovery, and may not achieve the same functional outcome as the original implant — making the harm to patients who required revision due to the packaging defect both medically significant and economically substantial. Class action and mass tort litigation consolidated in federal courts sought compensation for patients in these circumstances from Exactech and its private equity owner at the time the defect originated.

Quality System Failures and Detection Gaps

The Exactech case raised fundamental questions about the quality management system the company had in place for detecting packaging nonconformances over an extended production period. FDA-regulated medical device manufacturers are required under the Quality System Regulation to maintain procedures for detecting, documenting, and correcting nonconforming products before they reach patients. A packaging defect that persisted for over a decade without detection suggests a quality system failure that went beyond a single production error — it implies that the incoming inspection procedures for packaging materials, the in-process controls for packaging operations, and the periodic quality reviews of product specifications were all insufficiently robust to catch a deviation that had material patient safety implications. The FDA's inspections of Exactech's manufacturing operations following the recall examined these quality system elements, and any observations issued through Warning Letters or regulatory action letters following those inspections represented additional regulatory accountability beyond the recall itself.

Have documents relevant to this story? Reach us through our tips channel.